title: Low-dose aspirin and survival from lung cancer: a population-based cohort study.
abstract: BACKGROUND
  Preclinical evidence suggests that aspirin may inhibit lung cancer progression. In a large cohort of lung cancer patients, we investigated whether low-dose aspirin use was associated with a reduction in the risk of lung cancer-specific mortality.
  
  
  METHODS
  We identified lung cancer patients from English cancer registries diagnosed between 1998 to 2009 from the National Cancer Data Repository. Medication usage was obtained from linkages to the UK Clinical Practice Research Datalink and lung cancer-specific deaths were identified from Office of National Statistics mortality data. Hazard ratios (HR) and 95 % confidence intervals (CI) for the association between low-dose aspirin use (before and after diagnosis) and risk of lung cancer-specific mortality were calculated using Cox regression models.
  
  
  RESULTS
  A total of 14,735 lung cancer patients were identified during the study period. In analysis of 3,635 lung cancer patients, there was no suggestion of an association between low-dose aspirin use after diagnosis and cancer-specific mortality (adjusted HR=0.96, 95% CI: 0.85, 1.09). Similarly, no association was evident for low-dose aspirin use before diagnosis and cancer-specific mortality (adjusted HR=1.00, 95% CI: 0.95, 1.05). Associations were comparable by duration of use and for all-cause mortality.
  
  
  CONCLUSIONS
  Overall, we found little evidence of a protective association between low-dose aspirin use and cancer-specific mortality in a large population-based lung cancer cohort.
authors.affiliation: Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University Belfast, Belfast, UK. u.mcmenamin@qub.ac.uk.
authors.forename: Úna C
authors.initials: ÚC
authors.lastname: Mc Menamin
authors.affiliation: Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University Belfast, Belfast, UK. c.cardwell@qub.ac.uk.
authors.forename: Chris R
authors.initials: CR
authors.lastname: Cardwell
authors.affiliation: School of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, UK. c.hughes@qub.ac.uk.
authors.forename: Carmel M
authors.initials: CM
authors.lastname: Hughes
authors.affiliation: Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen's University Belfast, Belfast, UK. l.murray@qub.ac.uk.|Centre of Excellence for Public Health (NI), Centre for Public Health, Queen's University Belfast, Belfast, UK. l.murray@qub.ac.uk.
authors.forename: Liam M
authors.initials: LM
authors.lastname: Murray
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D016022:Case-Control Studies; D015331:Cohort Studies; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D001241:Aspirin